The synthetic antiviral drug arbidol inhibits globally prevalent pathogenic viruses

Eve Isabelle Pécheur, Viktoriya Borisevich, Peter Halfmann, John D. Morrey, Donald F. Smee, Mark Prichard, Chad Mire, Yoshihiro Kawaoka, Thomas Geisbert, Stephen J. Polyak

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Arbidol (ARB) is a synthetic antiviral originally developed to combat influenza viruses. ARB is currently used clinically in several countries but not in North America. We have previously shown that ARB inhibits in vitro hepatitis C virus (HCV) by blocking HCV entry and replication. In this report, we expand the list of viruses that are inhibited by ARB and demonstrate that ARB suppresses in vitro infection of mammalian cells with Ebola virus (EBOV), Tacaribe arenavirus, and human herpesvirus 8 (HHV-8). We also confirm suppression of hepatitis B virus and poliovirus by ARB. ARB inhibited EBOV Zaire Kikwit infection when added before or at the same time as virus infection and was less effective when added 24 h after EBOV infection. Experiments with recombinant vesicular stomatitis virus (VSV) expressing the EBOV Zaire glycoprotein showed that infection was inhibited by ARB at early stages, most likely at the level of viral entry into host cells. ARB inhibited HHV-8 replication to a similar degree as cidofovir. Our data broaden the spectrum of antiviral efficacy of ARB to include globally prevalent viruses that cause significant morbidity and mortality.

Original languageEnglish (US)
Pages (from-to)3086-3092
Number of pages7
JournalJournal of Virology
Volume90
Issue number6
DOIs
StatePublished - 2016

Fingerprint

antiviral agents
Antiviral Agents
Zaire Ebola virus
Viruses
viruses
Ebolavirus
Human herpesvirus 8
Hepatitis C virus
infection
Arenavirus
Vesiculovirus
Enterovirus C
Human Herpesvirus 8
Hepatitis B virus
Orthomyxoviridae
Hepacivirus
morbidity
glycoproteins
Ebola Hemorrhagic Fever
Infection

ASJC Scopus subject areas

  • Immunology
  • Virology

Cite this

Pécheur, E. I., Borisevich, V., Halfmann, P., Morrey, J. D., Smee, D. F., Prichard, M., ... Polyak, S. J. (2016). The synthetic antiviral drug arbidol inhibits globally prevalent pathogenic viruses. Journal of Virology, 90(6), 3086-3092. https://doi.org/10.1128/JVI.02077-15

The synthetic antiviral drug arbidol inhibits globally prevalent pathogenic viruses. / Pécheur, Eve Isabelle; Borisevich, Viktoriya; Halfmann, Peter; Morrey, John D.; Smee, Donald F.; Prichard, Mark; Mire, Chad; Kawaoka, Yoshihiro; Geisbert, Thomas; Polyak, Stephen J.

In: Journal of Virology, Vol. 90, No. 6, 2016, p. 3086-3092.

Research output: Contribution to journalArticle

Pécheur, EI, Borisevich, V, Halfmann, P, Morrey, JD, Smee, DF, Prichard, M, Mire, C, Kawaoka, Y, Geisbert, T & Polyak, SJ 2016, 'The synthetic antiviral drug arbidol inhibits globally prevalent pathogenic viruses', Journal of Virology, vol. 90, no. 6, pp. 3086-3092. https://doi.org/10.1128/JVI.02077-15
Pécheur EI, Borisevich V, Halfmann P, Morrey JD, Smee DF, Prichard M et al. The synthetic antiviral drug arbidol inhibits globally prevalent pathogenic viruses. Journal of Virology. 2016;90(6):3086-3092. https://doi.org/10.1128/JVI.02077-15
Pécheur, Eve Isabelle ; Borisevich, Viktoriya ; Halfmann, Peter ; Morrey, John D. ; Smee, Donald F. ; Prichard, Mark ; Mire, Chad ; Kawaoka, Yoshihiro ; Geisbert, Thomas ; Polyak, Stephen J. / The synthetic antiviral drug arbidol inhibits globally prevalent pathogenic viruses. In: Journal of Virology. 2016 ; Vol. 90, No. 6. pp. 3086-3092.
@article{425a8f03c30244cb92ea805487a281b2,
title = "The synthetic antiviral drug arbidol inhibits globally prevalent pathogenic viruses",
abstract = "Arbidol (ARB) is a synthetic antiviral originally developed to combat influenza viruses. ARB is currently used clinically in several countries but not in North America. We have previously shown that ARB inhibits in vitro hepatitis C virus (HCV) by blocking HCV entry and replication. In this report, we expand the list of viruses that are inhibited by ARB and demonstrate that ARB suppresses in vitro infection of mammalian cells with Ebola virus (EBOV), Tacaribe arenavirus, and human herpesvirus 8 (HHV-8). We also confirm suppression of hepatitis B virus and poliovirus by ARB. ARB inhibited EBOV Zaire Kikwit infection when added before or at the same time as virus infection and was less effective when added 24 h after EBOV infection. Experiments with recombinant vesicular stomatitis virus (VSV) expressing the EBOV Zaire glycoprotein showed that infection was inhibited by ARB at early stages, most likely at the level of viral entry into host cells. ARB inhibited HHV-8 replication to a similar degree as cidofovir. Our data broaden the spectrum of antiviral efficacy of ARB to include globally prevalent viruses that cause significant morbidity and mortality.",
author = "P{\'e}cheur, {Eve Isabelle} and Viktoriya Borisevich and Peter Halfmann and Morrey, {John D.} and Smee, {Donald F.} and Mark Prichard and Chad Mire and Yoshihiro Kawaoka and Thomas Geisbert and Polyak, {Stephen J.}",
year = "2016",
doi = "10.1128/JVI.02077-15",
language = "English (US)",
volume = "90",
pages = "3086--3092",
journal = "Journal of Virology",
issn = "0022-538X",
publisher = "American Society for Microbiology",
number = "6",

}

TY - JOUR

T1 - The synthetic antiviral drug arbidol inhibits globally prevalent pathogenic viruses

AU - Pécheur, Eve Isabelle

AU - Borisevich, Viktoriya

AU - Halfmann, Peter

AU - Morrey, John D.

AU - Smee, Donald F.

AU - Prichard, Mark

AU - Mire, Chad

AU - Kawaoka, Yoshihiro

AU - Geisbert, Thomas

AU - Polyak, Stephen J.

PY - 2016

Y1 - 2016

N2 - Arbidol (ARB) is a synthetic antiviral originally developed to combat influenza viruses. ARB is currently used clinically in several countries but not in North America. We have previously shown that ARB inhibits in vitro hepatitis C virus (HCV) by blocking HCV entry and replication. In this report, we expand the list of viruses that are inhibited by ARB and demonstrate that ARB suppresses in vitro infection of mammalian cells with Ebola virus (EBOV), Tacaribe arenavirus, and human herpesvirus 8 (HHV-8). We also confirm suppression of hepatitis B virus and poliovirus by ARB. ARB inhibited EBOV Zaire Kikwit infection when added before or at the same time as virus infection and was less effective when added 24 h after EBOV infection. Experiments with recombinant vesicular stomatitis virus (VSV) expressing the EBOV Zaire glycoprotein showed that infection was inhibited by ARB at early stages, most likely at the level of viral entry into host cells. ARB inhibited HHV-8 replication to a similar degree as cidofovir. Our data broaden the spectrum of antiviral efficacy of ARB to include globally prevalent viruses that cause significant morbidity and mortality.

AB - Arbidol (ARB) is a synthetic antiviral originally developed to combat influenza viruses. ARB is currently used clinically in several countries but not in North America. We have previously shown that ARB inhibits in vitro hepatitis C virus (HCV) by blocking HCV entry and replication. In this report, we expand the list of viruses that are inhibited by ARB and demonstrate that ARB suppresses in vitro infection of mammalian cells with Ebola virus (EBOV), Tacaribe arenavirus, and human herpesvirus 8 (HHV-8). We also confirm suppression of hepatitis B virus and poliovirus by ARB. ARB inhibited EBOV Zaire Kikwit infection when added before or at the same time as virus infection and was less effective when added 24 h after EBOV infection. Experiments with recombinant vesicular stomatitis virus (VSV) expressing the EBOV Zaire glycoprotein showed that infection was inhibited by ARB at early stages, most likely at the level of viral entry into host cells. ARB inhibited HHV-8 replication to a similar degree as cidofovir. Our data broaden the spectrum of antiviral efficacy of ARB to include globally prevalent viruses that cause significant morbidity and mortality.

UR - http://www.scopus.com/inward/record.url?scp=84961160885&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961160885&partnerID=8YFLogxK

U2 - 10.1128/JVI.02077-15

DO - 10.1128/JVI.02077-15

M3 - Article

VL - 90

SP - 3086

EP - 3092

JO - Journal of Virology

JF - Journal of Virology

SN - 0022-538X

IS - 6

ER -